The US Supreme Court Chief Justice Roberts has denied Teva’s application for an injunction seeking to prevent launch of a generic version of Copaxone pending the Supreme Court’s decision on Teva’s appeal. This has cleared legal hurdle for Mylan & Natco Pharma to launch the same at market formation. This is the second time that the Chief Justice has denied Teva’s request for such an injunction.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
